Ready 8-Ks
27
Latest filing
May 20, 2026, 5:16 PM ET
Top materiality
0.85
Event mix
other_material ×13 · regulatory ×6 · leadership ×3
Sentiment
8 pos · 7 neg · 12 neu
Latest earnings
reported 2025-FY
-
Shareholders approve reverse stock split, dilutive share issuances, and 2025 equity plan at cbdMD annual meeting
Reverse stock split from 1:2 to 1:10 approved, board to set ratio within one year.
-
cbdMD buys Bluebird Botanicals CBD e-commerce assets for 425k shares plus 525k earnout
Acquired substantially all assets of Gaia Botanicals d/b/a Bluebird Botanicals: brand, domain, trademarks, inventory.
-
cbdMD regains NYSE American compliance; BC indicator removed Dec 8, 2025
Received NYSE American letter Dec 5, 2025 confirming compliance with Sections 1003(a)(i) and (ii).
-
cbdMD Q4 net sales up 3-5% YoY; FY net loss improves to ~$2M from $3.7M
Net sales for fiscal 2025 expected $19.1–19.3M vs $19.5M prior year.
-
cbdMD converts all Series A Preferred to common, effects 1-for-8 reverse stock split
All 5,000,000 outstanding 8% Series A Preferred shares automatically converted into 65,000,000 common shares on May 6, 2025.
-
cbdMD shareholders approve automatic conversion of Series A Preferred Stock into common at 13:1
Shareholders approved automatic conversion of each Series A Preferred share into 13 common shares, eliminating $6.7M in accrued dividends and $4M annual dividend obligations.
-
cbdMD fully converts remaining $56K senior secured notes to equity, now debt-free
Remaining $56,000 Senior Secured Convertible Notes converted to common stock on Jan 14, 2025.
-
cbdMD reduces convertible note debt to $56K; issued 609K shares; Q1 cash ~$2.1M
Convertible note principal reduced to ~$56,000 as holders converted ~$309,000 principal plus accrued interest.
-
cbdMD receives additional NYSE American noncompliance notice for equity under $2M
Stockholders' equity $1,963,417 as of Sep 30, 2024, below $2M threshold; losses in 4 of 5 recent fiscal years.
-
cbdMD gets NYSE American plan acceptance for listing; equity at $3.1M, deadline Dec 2025
NYSE American accepted cbdMD's plan to regain compliance; plan period through Dec 5, 2025.
-
cbdMD acquires 'CBD MD' trademark from Majik Medicine for cash/stock; settles litigation
Paid $100k cash on closing; will pay $50k annually for 4 years ($300k total) and issued 75k shares of common stock (50k more in year 2).
-
cbdMD receives NYSE American acceptance of compliance plan; faces Dec 5, 2025 deadline
Stockholders' deficit of $3.1M as of March 31, 2024; non-compliance with $4M equity requirement.
-
cbdMD settles former office lease, expects ~$780K in total gains
Paid $255K to satisfy all past due obligations under former lease; mutual release executed.
-
cbdMD receives NYSE American delisting notice for equity shortfall; must submit compliance plan by July 5, 2024
Stockholders' equity was $3.1M as of March 31, 2024, below $4M minimum required by Section 1003(a)(ii).
-
cbdMD appoints new CEO/CFO, Chairman, and CAO; shareholder vote rejects Series A automatic conversion
Bradley Whitford appointed Chief Accounting Officer, Treasurer, Secretary; annual base salary $200,000.
-
cbdMD enters forbearance on sublease default, moves executive offices
Behind on rent since Sep 2023; default notice and summary ejectment filed Feb 2024.